Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism.

S Kuhle, D A Lane, K Jochmanns, C Male, P Quehenberger, K Lechner, I Pabinger

Journal: Thrombosis and haemostasis 2002;86(4):1007-11

PMID: 11686316

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

We report 5 children from 3 families with homozygous antithrombin deficiency type II affecting the heparin binding site (99 Leu to Phe mutation). Four children had severe spontaneous thromboembolic events (deep leg or caval vein thrombosis, ischaemic stroke) at one week, 3 months, 13 and 14 years of age. The fifth patient, a 17 year-old boy was asymptomatic. Early manifestation of homozygous deficiency calls for prompt and accurate diagnosis. In doubtful cases genetic analysis is required. Long-term oral anticoagulation should be considered in affected individuals.

Address: Dept. of Paediatrics, Vienna University Hospital, Austria.

Link outs

Free resources

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Molecular Biology Databases:

https://biocyc.org/gene?orgid=HUMAN&id=HS04156

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Adolescent, Age of Onset, Amino Acid Substitution, Antithrombin III, Antithrombin III Deficiency, Binding Sites, Brain Ischemia, DNA Mutational Analysis, Female, Genetic Predisposition to Disease, Genotype, Humans, Infant, Infant, Newborn, Infarction, Middle Cerebral Artery, Male, Mutation, Missense, Point Mutation, Thromboembolism, Thrombophilia, Venous Thrombosis, Yugoslavia